H1N1 in the view of Festivals

One of the largest sommer festival is the hungarian SZIGET Festival. It will begin tonight in the Hajógyári sziget, and ends at 15th of August.



The mass that will be there has to be protected from the new culminating , called H1N1 which has been never circulated amongs human. Therefor it is good to be acquainted with the person-to-person spreading ability of this dangerous virus.

The background of the H1N1

H1N1 is a new influenza virus, we are emphasing: new, which is being spread all over the world. In some cases it can be unpleasant. Its major symptoms are the following: fever, dry cough, sore throat, body aches, headache, chills, runny nose and extreme fatigue, sometimes vomiting and diarrhoea. It is easy to catch through the following ways:
- handshaking: The influenza virus attaches easily to your fingers and areas such as door handles and may be contracted when you shake hands.
- coughing, sneezing: by this way the influenza can get into the bend of your arm


That’s why we recommend to avoid covering your mouth with your arms, and washing them often, even if you have a norvegian-fishery arms, which are resisting to anything bad things. It can be recommended if you use some alcohol-based cleaning stuff, outside and inside (beer-yeah).

The vaccine

When the mankind faces with similar pandemic challenges they try to figure out which alternative is the best way to subdue the attacker. The vaccine proved the best way. In Hungary, the new vaccine production is urged and WHO has been investigates the safety concerns of it and didn’t find any of them. In the end of September will available the new vaccine, at that time will be approved its release.

Sziget Commando

Sziget commando has been estabilished to fend off the new influenza. Sziget’s Health Service is ready to take a leap to the precaution measures when the situation needs. They stocked with some medicine, but in the case of direct observation of H1N1’s symptomes a helicopter will deliver the patients to the László Szent Hospital, and every ill-people will be reported to the National Epidemiology Centre.

Innovative milieu

I've just been writing in co-work a study about science and technology policy, referring to its opportunities and performances on higher education. It is in tight connection with innovation and research and development processes and theories. Ultimately, with the economic growth theories. Nowadays there is a broadly accepted, consencual view that the knowledge based society can be the best way to subdue the fiercy global competition.

After "Capitalism, Socialism, and Democracy"

Once upon a time, the writer of "Capitalism, Socialism and Democracy" entitled book, Joseph A. Schumpeter said that the innovation is important and can trigger / just for You ;-) / the potential growth rates. In order to some way we get us to be innovative, and have innovative milieu we have lots of formations, and incentives method.

Numerous researcher's study suggest that we have to concentrate our resources, and estabilish business networks and clusters with higher education systems.

For a long time, the applied and basic research works did'nt get the right emphases, but now, the European Union has revealed its programs, and the resented lack of basic research's focus will be more important in the future.

Specific example

European Cancer Cluster (ECC) Partnering 2009 event

The Cancer-Bio-Health Cluster and the Oslo Cancer Cluster are organising the European Cancer Cluster (ECC) Partnering 2009 event to take place on 3 and 4 September in Toulouse, France.

The event will bring together business representatives, investors and scientists from the fields of diagnostics, therapeutics, drug delivery, medical devices and medical imaging.

Keynote speeches, presentations and discussion roundtables will address such topics as:
- evaluating the oncology industry;
- building partnerships with investors;
- the Innovative Medicines Initiative (IMI).

Beyond that, the aim is to build a 'Europe of the cancer clusters' and to support companies, spin-offs, small and medium sized enterprises (SMEs) and large pharmaceutical enterprises in building new partnerships.

For further information, please visit this.

Discover the Unimedic opportunities

Befor I make an "in medias res" beginning, I would like to share some private information about the preliminary circumstances of this post. I met with an invaluable girl three months ago. She has true friends, and one of them had decided with her brother that they use their consummate knowledges in medical sphere and take a leap and provide services for people suffering from cardiovascular problems. This is very important, I have been reading the Science and Nature since long time. Every cardiovascular-related column inform us about nowadays more early deaths are related to cardiovascular events (like stroke and heart attack) than any other causes altogether. Although there are devices for detecting late stage, irreversible cardiovascular diseases, the real, silent cause of them, arterial stiffness have not easily been detectable yet.

Breakthrough in Early Diagnosis of Arteriosclerosis

The TensioClinic Arteriograph analyses the cardiovascular system from five highly important aspects to assure Comprehensive Cardiovascular Risk Assessment. Measuring Central and Peripheral Blood Pressure, Arterial Stiffness (PWV & AIx), Cardiac fitness and considering Classical Cardiovascular Risk Stratification (Framingham, SCORE), Arteriograph enables detecting the real, individual risk even at the early, reversible stage. Numerous EU references are available for reinforcing the significance of this unique screening device, which is also ideal for evaluating the efficiency of applied cardiovascular therapy and for follow up of diabetic patients, too.

Unimedic Limited:

early non-invasive diagnosis of subclinical atherosclerosis and arteriosclerosis, screening by Arteriograph, measuring arterial stiffness i.e. Augmentation index AIx, Pulse Wave Velocity PWV, Central Systolic Blood Pressure SBPao and cardiac fitness, arterial function evaluation; Framingham and SCORE classical risk stratification, comprehensive cardiovascular risk assessment, prevention of vascular endothel dysfunction, hypertension, myocardial infarction, heart attack, plaques, stroke and coronary heart disease.

Recommend to gain more!

Vulpine molecules to force cancered cells for self-annihilation

Nowadays, when we can see ongoing bailouts all over the World, strictly in economically way, we do not have to sojourn a lot with this crisis, because this economic juncture is not comparable with human cancer crisis. Economic slowdown, breakdown or whatever we call it, some beauty day will reach its end, but cancer in human body is about to be insurmontable thing, which doesn’t say good bye when it has raved itself out.

Bait-mechanism in DNA

If we want to face with these sassy disease, we must cope with our wide opened eyes. As we know long time, there are cancer cells which resist radiotherapy, but, there is a bait opportunity. Like in fishing, when our lovely and consummate stripling kid with all knowledgement we need, so he come to us and help to bait, feeding to setting up the target… but all we know, the major reason is that our adorable but discontended housewife will be satisfied with (every moments in a men’s life is about to this) But, take for instance these bait-mechanism during the explanation the newest possibility in cancer research.

As i mentioned, there are cells, which highly resistents to ray-treatments. But, now, franche-researchers developed so-called bait-molecules and they conduce to start an apoptosis (self-extermination) process of these cells.

Cancer can believe, for God sake

The aim of chemotherapy and ray-treatment is to destroy cancered cells. One of the most efficient method to hinder the cancered cells’ reproduction is when erudites try to generate ’fractures’ on DNA spiral. But, some cells are able to regenerate itself, and this was the biggest problem until nowadays. These cells are shrewd, intelligent, and they watch the extent of its damage. And this is the key, because when they believe that, this damage is too enormous to can regenerate, they voluntarily choose self-extermination (apoptosis). And that is we want to not Carmen Elektra (i must confess, i don’t want Elektre, a want a real superbly Woman in sexy hearty-lingerie).

Marie Dutreix and his research team has created this ’god’ bait-molecule, which is capable enough to make these cells believe their damage-grade is too much and say good bye or ja mata. The belief is not real, but necessery to achieve apoptosis through this programmed cells-death way.

Bait-molecules block the regeneration-ability of cancered cells. Matter of fact, these molecules are little DNA-sections, and can cause fractures in two filament of the cancer-DNA. And eventuelly these cells like hell are urging themselves to choose the benign extermination. This is triumphant for mankind.

Bait-molecules have already prooved its effectivity on rats and mice. According to the experiments, this method is contribute with 75-100 percantage to destroy (in case of melanom and brain-cancer) trissues without any side effects.

For more information for enthusiastic-readers: http://www.dna-therapeutics.com/

Good Interaction between Cancer Research and Transplantation

However, Yesterday We have a big mulled wine party, now, im ready to share with you an intresting news in the light of:

"can it happen ? good side effect of a cancer-medicine" theme.

And yes, i hope mulled wine can eliminate malignant cells too.

Transplantation and bortezomib

According to the Transplantation expert magazine, We are luckily living in our Globus, which has a "bortezomib" concoction with positiv side effect for those who previously were operated with transplantation.

New vaccine, decreasing antibody

This new vaccine was tested by six people, where kidneys were rejected their bodies. But with the usage of this vaccine experten and physicians could ward the rejection process off, and at last, it stopped. Every time they used this product, the rejection-process stopped, and they could successfully decrease the antibody production.

The fact that, this way could be a better than ever in the treatment of transplantation and autoimmune diseases.

A couple years before, bortezomib considerably contributed to the treatment of myeloma multiplex. This concoction is a so-called: proteasoma-inhibitor.

How does it works?

There are cells, and in these cells we can find materials we wanted to be demolished. Well, at first, these have to face with ubikvitin proteinpack. Just like an deadly kiss, namely, after this romantic affair, the protein is willing to walk into one of those incinerator (proteasoma) which are existing that place. And than, it will be demolished by ensimcomplexes.

Bortezomib can block proteasomes in malignant cells.

Good way,

My way, or the highway - singing Fred Durst, it's just a question.

Doctors and the Web

As we well know, pharmaceutical industry has been spending

enormous volumen of money on online marketing.

According to the statement from TNS Media Intelligence the world biggest medicinemaker firm, Pfizer Inc. spent 65 million dollar in period between january and september 2006. And naturally, the spending ablility and willingness were growing during the last years until nowadays, when a new historically juncture has arised.

There are some missbelief that we have to re-consider in connection with pharma industry on Internet.

1. "doctors are not surfing on the Internet so much" - it's baloney. Survies and another datas showed that 82% of oncologists, 60% of psychiatrists, 54% of neurologists, and last but not least 68% of cardiologists use the internet regularly.

2. "it's difficult to reach doctors on the Internet" - it's simply not true. As a result of mentioned missbelief, doctors are available ont he Internet. They are quastionable, we can share our problems, dubious asks and opinions. Numerous portal are running with the aim of online webdoctoring. These sites are able to bring leading edge technology to enhance your medical information experience. We can find all of our medical answers and needs right there. These sites are formed like any other forums. Take for instance http://webdoctor.nexenservices.com/ ;

3. „Those doctors who use Internet are allways looking for non-professional columns and stuffs” – i can assure you, they do such a thing, but another things too.

Did you know physicians are more likely than consumers to use the web and other technologies to access information? A new white paper from Manhattan Research,

‘Physician and the Web 2.0’

, states that

physicians are embracing Web 2.0 technologies

-- podcasting, social media networks, online video, blogs -- in large numbers. In fact, the study notes that more than 25,000 physicians are actively reading and posting to blogs and more than 80,000 doctors participate in online communities. For these physicians, the online landscape is evolving into an interactive forum for information sharing and education. And it’s not just the young docs who grew up on the Internet -- the report notes that an older generation of more experienced physicians want to share their ideas through this new interactive medium.

Think of all the innovative ways you can share health, medical and treatment information with physicians. Evolve your marketing strategies to make your information portable and available in new formats. Now is the time, because your doctor is more than just online.

Oldschool and The New One

In the course of applying newest supplementary medicine people can prevent the brain-catastrophy with a better probability, be more accurate, people can abate the risk of brain-catastrophy. It was the theme of the European Heart-therapeutists Congress 2008 in München.




The research-team has been carrying out a speciel examination for long time. With the involvment of more than 4600 patient the erudites were led to the conclusion – patients stem from 550 different hospital, 36 countries – that in the case of brain-catastrophy-prone people, the artium fibrallation is in an unnormal konstellation.

Stuart J. Conolly said, during the probe, there was a random choosing methode, thus researchers formed 2 group. One group has been treated by the well-knowned medicines, another one was treated by the same way, with the difference, that they also got the newest medicine, called dronedarone. All patient were ranked in the high-risks group. They have extremely serious problems with their cardiovascular-system.

The outcome?

The prone for the brain-catastrophy could curb with 34 percentage from those patient who were treated by dronedarone too. An intrinsic note, they used an appropriate thrombotic-proof medicine too.

We are looking for the using of this medicine, hope, it will sooner than we can think…

Prostate-cancer and the Hope

prostate cancer; prostate cancer research

Erudites think they almost have an efficient answear for the most deadly cancer-type from which men are suffering nowdays. As We (unfortunately) know, the aggressive prostate-cancer is lethal and the most harmful type of some of cancer-types. More than 10 thousand people per annum have to face with the deadly cancer only in the United Kingdom. It is so stern, and aggressive, so far the chemotherapy was a little hope-ray, but as it comes to light the chemotherapy merely can provides a little bit longer life.

prostate cancer alternative treatment

In turn, research workers might take control of its hormon-making mechanism. According to facts, tumors can expanse and broaden theirs territory because of testosterone. But, so far, they don’t recognize that tumor can produce testosterone too, that is to say, they can be treated as a self-sufficient killers, tumor can trigger its expansion.

Now, prospectors developed a new medicine – Albiraterone - which is in testing-phase, but its achivements are promising. It could be the cure against the aggressive prostate-cancer. Cliniq-investigations have showed that it works in 80 percentage of all cases.

How does it work? Albiraterone as an antimatter is able to block the producing mechanism of testosteron of tumors. As far as erudites concerned, its effectiveness is enough to hope it will be the solvation. So far, they managed tests on 1200 voluntary-patient, among the candidates there were a lots of people who have been reporting about positive progress.

According to the test of Journal of Clinical Oncology,shrinkings of tumors were obviously, and the volume of emissed protein were unambiguously moderated.

There is a HOPE. But, naturally, we have to wait, until the full of tests, and side effects will be known, and then… hope becomes fact.

Coping with Alzheimer

Erudites developed a new medicine, which may reverse the Alz-Heimer process.

These scientiest made a very genuine mechanism, through its efficiency they able to reverse the malignant Alz-Heimer's symptomes. This medicine can make a connection with the brain-cells, due to the animal-tests, it prooved appropriate opportunity. Scientist are in great hope that they can testing on human side too as soon as possible.



Medicine is blocking enzimes, which are blamable to cause brain-placks (placks contain calcium, lard eq) have enormous and key-role in the evolvation of Alz-Heimer. If everything goes well, this medicine will be available in trading circulation in 10 years. The question is, whether the medicine is able to get through the human blood-brain-hurdle. When the medicine was directly injected in brains of rats, the consequence was a telling decreasing of the volume of brainplacks (the number of placks were eliminated with 50 percentage in 4 hours).

DermaVir Bandage Against AIDS

There are so many serious virus, bacteria all over the World evolved, emitted, designed by many different ways (im writing in this way, 'cause people can estabilish deadly by voracious inhuman behaviorism).

AIDS, this 4 words mean a lot for those who got contact with this virulent contagion, or keeping their eyes open and watching the news. According to the European Commission, more and more people get infection year by year, especielly from the range of 15 - 25 age, and the survey added: this is among heterosexual people. So far as im concerned, this means that in the age class of juvenile, teenage this is very partycular problem. They do not care enough of themselves, they do not be enough prudence.





Thousands of people in pharmaceutical sector have been trying to develope a new medicine, a new prodecure in the last decade to ward off this deadly infection.

In Hungary, an atomic ray of hopeness has sparked in the course of estabilishing a new bandage - called aids bandage - against this volarious epidemic. The new solid opportunity against AIDS experimented by Professor Julianna Lisziewicz in United States will be introduced and available in 4-5 years. There are not any other similar medicine in the World with the effectiveness of this so-called therapy vaccine bandage, Professor Julianna said.

This is not mainly a preventive mechanism, this has to be used during the illness, as a treatment. In Practise the bandage is stinked to the back of people, where the vaccine yielded by DNA of HIV virus reaches Langerhans-cells. Cells are discovering the active substance of DermaVir (this is the name of medicine) and they get its encoded information travelled to lymph node, this process is inducing killer-cells which devour infected cells.

This method is safe for people, it was proofed by many tests.

Health Includes Body and Soul - Possibilities in Hungary

Firstly, i must confess honestly recently i hadnt had enough
time to post new and attracting stuffs. But, now, i decided that
it would be benign if we take a trip in the sphera of the therapy
process, methods to discover how can people ease their
pain with the newest and classics therapy-methods.

Im just about to bolster another blogger's theme. Because our
first visit has taken place in Hungary, especielly in its most notable
therapy and spa centrum, Hajdúszoboszló. Do not hesitate and click on the mentioned name to widen mind in the light of this theme.

As we know the therapeutics has got some scope in wide range. From the healthy hot springs through the pleasure park, where are some provided speciel processes which facilitate the tranquil healing up. Hungary has a lot of opportunities out of these, one of the biggest favoured place is Hajduszoboszlo. Make a little ad for it, it is a must, but, it is without any capitalization goals, its a pure object, to make greater renown for this health paradise, for the sake of people.

Are we close ties with God?

"God has not given us any disease for which he has not provided a remedy." Paracelsus

I have been crawling and surfing on the Internet, and at last bumped into a very gripping
doctor of TCM thesis by Ricardo Serrano, entitled: Cure and Cause of Cancer is Within You.

"The cure and cause of cancer is within you. The cause of cancer is a weakening of your immune system (Wei Qi) which is termed Chronic Immune (Wei) Dysfunction Syndrome (CIDS). I will elaborate more on this theory at the Cause web page and you will know why Traditional Chinese Medicine works.

The cure for cancer is strengthening your immune system (Wei Qi) which can be done naturally with powerful tools such as herbal formulas (detoxification and nourishment), meditation, acupuncture/moxibustion, pranic healing, and nutritional supplementation in an integrated manner. I will elaborate more on this at the Cure web page.

My theories and system of cure is rational, time tested and scientifically proven for centuries according to Traditional Chinese medical theory on strengthening Wei Qi as practiced in mainland China and everywhere in the world.

I believe that Our Creator provides us with powerful tools from nature and within us to deal with our health challenges as long as we have faith in the healing power within ourselves and use Mother Earth's herbs and special foods."

He looks convincing, its time to be hopeful mankind's ability is enough to reveal all causes of cancers by and by. As im concerned: im flurried.

Cancer Research a'la hungarian method

Huge hungarian achievement in cancer research

Professor Istvan Majoros' invention named dendrimer can devour directly the sick cells.

It will be the biggest performance in the story of the hungarian cancer research if the artificial dendrim molecule adaptable on people too.


 
According to the erudite the cell can be treated as trojan woodhorse able to dispatch some medicine to the cancered cells, which annex it - in the hope of the important vitamines - whereby the traditional kemotherapy might be readily superfluos.

The new method can only deploy for the treatment of the evolved cancer, in turn its dosing can be revised by prefrences, and it has not got any spillover.

The professor who lives in USA since 1990 is trusting in connection with the application of the new developed method, he said, in the course of animal tests they destroyed the breast-cancer successfully. At this moment the animal attempts are going, and the deploying of the new dendrin is likely to be a grave counterpart, and cope with whatever cancer types.

The discovery was welcomed keenly by the profession, for example Michigan subsidies the professor's research with notable sum of money. Istan Majoros said, all terms are available in the United States to the research, however, there are very stringent yearly probes, in which the researcher groups are examined, and make the subsidies in line with the achievements.

Istvan Majoros added the sick people are the most important for himself than the money, he tries to do his best in order to rise the quality level of the Hungarian cancer research.

The Cost of Developing a New Drug

This particular column stems from the CBO's Study, named: Research and Development in the Pharmaceutical Industry - i would like to express my satisfaction and happiness in connection with this study, read it because it is advisable:

Research and development costs vary widely from one new drug to the next. Those costs depend on the type of drug being developed, the likelihood of failure, and whether the drug is based on a molecule not used before in any pharmaceutical product (a new molecular entity, or NME) or instead is an incremental modification of an existing drug.

Innovative Drugs
A recent, widely circulated estimate put the average cost of developing an innovative new drug at more than $800 million, including expenditures on failed projects and the
value of forgone alternative investments.1 Although that average cost suggests that new-drug discovery and development can be very expensive, it reflects the research strategies and drug-development choices that companies make on the basis of their expectations about future revenue. If companies expected to earn less from future drug sales, they would alter their research strategies to lower their average R&D spending per drug. Moreover, that
estimate represents only NMEs developed by a sample of large pharmaceutical firms. Other types of drugs often cost much less to develop (although NMEs have been the source of most of the major therapeutic advances in pharmaceuticals).

The study that produced that cost estimate also calculated how long it takes to develop a new drug and the relative contribution of capital costs to a drug’s total R&D costs. On average, developing an innovative new drug takes about 12 years, the study concluded, and a firm’s actual expenditures make up only about half of the total reported cost. The rest represents the financial cost of tying up investment capital in multiyear drugdevelopment
projects, earning no return until and unless a project succeeds. That “opportunity cost” of capital reflects forgone interest or earnings from alternative uses of the capital. (Opportunity costs are common to all innovative industries, but they are particularly large for pharmaceutical firms because of the relatively long time that is often required to develop a new drug.)

Research and development spending per NME has grown significantly in recent years, for various reasons. First, failure rates in clinical trials have increased, possibly because
of greater research challenges or a willingness to test riskier drugs in such trials. Second, larger drug firms are said to have shifted the focus of their development efforts away from drugs for acute illnesses and toward drugs for chronic illnesses. Drugs that treat chronic illnesses can be more expensive to develop because they often require larger and longer clinical trials. Third, greater technological complexity in drug development and greater specificity in disease targets have helped to raise average R&D costs, as firms now identify drugs with particular molecular characteristics rather than using trial-and-error methods
to find compounds that work in some desired way. Not all new molecular entities provide unique therapeutic functions. Many NMEs are so-called “me-too” drugs. Despite that name, they are not necessarily imitations of other drugs. Rather, they may be innovative products that lost the race to be the first drug on the market in a given therapeutic class (such as antidepressants, antibiotics, or antihistamines). Such products can benefit consumers by
competing with, and sometimes improving on, the pioneering drug in a class.

Facility of the year - hip hip drugsah!

2007 Facility of the Year Award Category Winners Announced

Five pharmaceutical manufacturing facilities located in China, Germany, Japan, and the United States have been selected as Category Winners in the third annual Facility of the Year Awards competition sponsored by ISPE, INTERPHEX, and Pharmaceutical Processing magazine. New enhancements to this year’s awards program include naming winners in five specific categories.

The companies and respective award categories include:
* Cook Pharmica, LLC, located in Bloomington, Indiana, USA, selected as winner of the Facility of the Year Award for Facility Integration
* Genentech located in Oceanside, California, USA, selected as winner of the Facility of the Year Award for Project Execution
* Shanghai Roche Pharmaceuticals, Ltd., located in Shanghai, China, selected as winner of the Facility of the Year Award for Project Execution Regional Excellence
* Taiyo Yakuhin Co., Ltd located in Takayama City, Japan, selected as winner of the Facility of the Year Award for Equipment Innovation
* Vetter Pharma-Fertigung GmbH & Co. KG located in Ravensburg, Germany, selected as winner of the Facility of the Year Award for Process Innovation

The Facility of the Year Awards competition is the premier global awards program focused on recognizing the innovation and creativity utilized by manufacturing facilities serving the regulated health care industry. By recognizing those manufacturers who are using new technologies both to improve the quality of their products while reducing the cost of producing medicines, the awards program promotes technological innovation across the industry. In consideration that the product development and research aspects of the pharmaceutical manufacturing industry generally get most of the attention, the Facility of the Year Awards program recognizes those who design, build, and operate world-class manufacturing facilities.

Being named a Category Winner generates unsurpassed opportunities for the applicant manufacturer and those organizations that designed, constructed, validated, and equipped the facility to showcase their ingenuity in facility design through various publicity initiatives. Moreover, the competition offers an unprecedented opportunity for submitting companies, category winners, and the Facility of the Year Award winner to motivate colleagues within the industry toward these advances through the sharing of industry-wide best practices within the global community.

“There is something truly remarkable and innovative about every single submission,” said Scott Ludlum, ISPE's Director of Business Initiatives. “
The five Category Winners hail from four different countries. This diversity demonstrates that the Awards program is a true reflection of the global nature of the pharmaceutical manufacturing industry,” said Ludlum.

Each of the submissions was reviewed by an independent, blue-ribbon judging panel of global representatives from the pharmaceutical design, construction, and manufacturing sectors.
“The addition of Category Winners to the 2007 Awards program significantly impacted the competition and effectively enabled the judges to properly acknowledge those facilities that stood out and deserve special recognition,” stated Andy Skibo, 2007 Judging Panel Chair, and Vice President Corporate Engineering and Capital Projects for Amgen.

Recognition at INTERPHEX

2007 Category Winners will be recognized and awarded during INTERPHEX2007, where thousands convene for the largest and most distinguished industry event taking place worldwide, which takes place from 24-26 April 2007.

The announcement of the coveted Facility of the Year Awards winner will take place at ISPE’s 2007 Annual Meeting in November at Caesars Palace in Las Vegas. ISPE’s Annual Meeting is the leading industry event attended by pharmaceutical manufacturing professionals where Category Winners will be recognized in front of their peers during ISPE’s keynote session. There will also be a separate Facility of the Year Awards display and a conference session featuring the Category Winners and Facility of the Year Award Winner.

Meet the 2007 Facility of the Year Judging Panel

Andy Skibo Judging Panel Chair VP Corp. Engineering and Capital Production Amgen
Nigel Barnes Vice President, Global Project Management GlaxoSmithKline.
Chaz Calitri Senior Director/Team Leader Pfizer Global Engineering
Christian Ilsoe Vice President Quality & Validation Assurance NNE A/S
Brian H. Lange, P.E. Director – Sterile & Packaging Operations Engineering Merck & Co., Inc.
Thomas G. Lyon Vice President Global Engineering Bristol Myers Squibb Co.
Shinichi Osada Chief Marketing Manager Hitachi Plant Technologies, Ltd.
Ulrich Rudow VP Worldwide Engineering and Real Estate Johnson & Johnson
Ronald Trudeau Vice President – Facilities Engineering Services Baxter Healthcare Corp.

Please, let me congratulate to winnwers, and express my profoundly appreciation.

Over The Counter Market

Over-the-counter medicines

The circulation having many of those medicines, which are available without prescriptions. The market of this medicines is called over-the-counter (OTC). The purchase of the OTC's articles are being treated as self-healing method, at least from the view of the doctor society. Besides, obviously it has a lots of perils. The OTC-articles - contrary to the medicines are subject to prescription - can be widely advertised.




Four advantages of the OTC:

- there are no need high-cost meetings of the doctor-patient
- generally, the health insurances do not support this medicines (this means: savings)
- this market can boost the good will of pharmacists
- can boost the health awareness of the people, the own responsibilities of the own health state

Accordint to the date of 1998, the OTC's medicines' turnover was $75 billion. The data shows that the reacher countries are spending more than the poorer.

Global Medicine Market Has Slightly Accelerated In 2006

According to the estimates of the last year throughout the World the value of the sold article of the chemists was 643 billion $, and it eclipsed the former value with 7 percentage – coming to light from the last released analysis of the IHS.

The measure of the medicine consumption is rising by far the biggest value: for instance it was 13 percantage in Latin-American region, and the market expanded with tenth in the Asian, African region.

In China, the market expansion showed a little deceleration: the market grew with eighth, it was a backlog compared with the last years.

The turnover of the pharmaceutical articles raised with 8,3 percantage in the U.S, it was the greatest value among the developed countries, due to the adjustment of the financial system.
In Europe the market has been slowing further, due to the gaining upon of the generic medicine.
The consumption was damping nearly 1 percant in Japan.

As for the product lines, the cholesterol-reducing, fatty acid controller are in greatest demand, in last year, they are purchased in 35,2 billion $ throughout the World.

Gold Age Of The Pharmaceutical Industry

According to the analists, the gold age of the pharmaceutical industry was between 1955 and 1985, but nowdays there are similar opportunities in this ramification. The mentioned date of the gold age can be described the following attributes:

- permanent growing market
- increasingly discovers of the new molecules
- full patent protection over the staple markets
- minimum 5 years monopol situation due to the breakthrough drugs
- slowly emerging of the generic markets
- almost full pricing independence in utmost markets
- good defined consumer market

The World Biggest Pharmaceutical factories in 1999

Firm Name and Annual Turnover (billion $)
1. Pfizer ( _23,15_ )
2. GlaxoSmithKline (_ 22,04_ )
3. AstraZeneca ( _14,29_ )
5. Bristol-Myers Squibb ( _13,28_ )
6. Novartis ( _12,41_ )
7. Johnson & Johnson ( _12,36_ )
8. Aventis ( _11,31_)
9. Pharmacia ( _10,25_ )
10. American Home Products ( _9,57_ )